481 related articles for article (PubMed ID: 10954022)
1. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
[TBL] [Abstract][Full Text] [Related]
2. Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy.
Piwowar A; Knapik-Kordecka M; Szczecińska J; Warwas M
Diabetes Metab Res Rev; 2008 Oct; 24(7):549-53. PubMed ID: 18613218
[TBL] [Abstract][Full Text] [Related]
3. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy.
Zhou H; Tan KC; Shiu SW; Wong Y
Nephrol Dial Transplant; 2008 Mar; 23(3):927-33. PubMed ID: 18065800
[TBL] [Abstract][Full Text] [Related]
4. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients.
Xu GW; Yao QH; Weng QF; Su BL; Zhang X; Xiong JH
J Pharm Biomed Anal; 2004 Sep; 36(1):101-4. PubMed ID: 15351053
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycosylation end products in patients with diabetic nephropathy.
Makita Z; Radoff S; Rayfield EJ; Yang Z; Skolnik E; Delaney V; Friedman EA; Cerami A; Vlassara H
N Engl J Med; 1991 Sep; 325(12):836-42. PubMed ID: 1875967
[TBL] [Abstract][Full Text] [Related]
6. Serum and urinary type IV collagen concentrations in the assessment of diabetic microangiopathy.
Banu N; Hara H; Egusa G; Yamakido M
Hiroshima J Med Sci; 1994 Dec; 43(4):123-33. PubMed ID: 7883578
[TBL] [Abstract][Full Text] [Related]
7. A novel advanced glycation index and its association with diabetes and microangiopathy.
Sampathkumar R; Balasubramanyam M; Rema M; Premanand C; Mohan V
Metabolism; 2005 Aug; 54(8):1002-7. PubMed ID: 16092048
[TBL] [Abstract][Full Text] [Related]
8. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis.
Gerdemann A; Lemke HD; Nothdurft A; Heidland A; Münch G; Bahner U; Schinzel R
Clin Nephrol; 2000 Oct; 54(4):276-83. PubMed ID: 11076103
[TBL] [Abstract][Full Text] [Related]
10. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.
Nakamura T; Fujiwara N; Sugaya T; Ueda Y; Koide H
Metabolism; 2009 Aug; 58(8):1185-90. PubMed ID: 19481229
[TBL] [Abstract][Full Text] [Related]
11. Plasma advanced glycation end products are decreased in obese children compared with lean controls.
Sebeková K; Somoza V; Jarcusková M; Heidland A; Podracká L
Int J Pediatr Obes; 2009; 4(2):112-8. PubMed ID: 18645732
[TBL] [Abstract][Full Text] [Related]
12. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.
Sebeková K; Gazdíková K; Syrová D; Blazícek P; Schinzel R; Heidland A; Spustová V; Dzúrik R
J Hum Hypertens; 2003 Apr; 17(4):265-70. PubMed ID: 12692571
[TBL] [Abstract][Full Text] [Related]
13. Temporal increases in urinary carboxymethyllysine correlate with albuminuria development in diabetes.
Coughlan MT; Forbes JM
Am J Nephrol; 2011; 34(1):9-17. PubMed ID: 21654162
[TBL] [Abstract][Full Text] [Related]
14. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related?
Sebeková K; Podracká L; Heidland A; Schinzel R
Clin Nephrol; 2001 Dec; 56(6):S21-6. PubMed ID: 11770807
[TBL] [Abstract][Full Text] [Related]
15. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property.
Nam SM; Lee MY; Koh JH; Park JH; Shin JY; Shin YG; Koh SB; Lee EY; Chung CH
Diabetes Res Clin Pract; 2009 Feb; 83(2):176-82. PubMed ID: 19111363
[TBL] [Abstract][Full Text] [Related]
16. Melatonin reduces urinary excretion of N-acetyl-beta-D-glucosaminidase, albumin and renal oxidative markers in diabetic rats.
Oktem F; Ozguner F; Yilmaz HR; Uz E; Dündar B
Clin Exp Pharmacol Physiol; 2006; 33(1-2):95-101. PubMed ID: 16445706
[TBL] [Abstract][Full Text] [Related]
17. Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy.
Ha SW; Kim HJ; Bae JS; Jeong GH; Chung SC; Kim JG; Park SH; Kim YL; Kam S; Kim IS; Kim BW
Diabetes Res Clin Pract; 2004 Aug; 65(2):167-73. PubMed ID: 15223229
[TBL] [Abstract][Full Text] [Related]
18. Association of haptoglobin phenotypes with markers of diabetic nephropathy in Type 2 diabetes mellitus.
Awadallah SM; Saleh SA; Abu Shaqra QM; Hilow H
J Diabetes Complications; 2008; 22(6):384-8. PubMed ID: 18413152
[TBL] [Abstract][Full Text] [Related]
19. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
20. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus.
Cha DR; Kim IS; Kang YS; Han SY; Han KH; Shin C; Ji YH; Kim NH
Diabet Med; 2005 Jan; 22(1):14-20. PubMed ID: 15606685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
